01

Who we are

02

MyGeneraTM

03

Product Pipeline

04

Research & Innovation

05

Partnership

06

News & Media

Massimiliano Cesarini Appointed CEO of Biogenera S.p.A.

Biogenera is pleased to announce the appointment of Massimiliano Cesarini as Chief Executive Officer and Chairman of the Board.

With a strong background in Life Sciences and a track record of leadership across the pharmaceutical and biotech sectors, Cesarini brings extensive experience in managing complex operations, international teams, and high-impact strategic projects. His profile combines scientific vision with a results-driven approach focused on innovation, sustainability, and long-term value creation.

A Strategic Moment for Biogenera

Massimiliano Cesarini’s arrival marks a key turning point for Biogenera, as the company prepares to launch its first Phase I clinical trial for BGA002, a first-in-class anti-gene oligonucleotide targeting the MYCN oncogene, a major driver of aggressive pediatric and adult cancers.

Under his leadership, Biogenera aims to:

  • Strengthen its position in the European biotech ecosystem
  • Expand its global network of strategic and scientific partnerships
  • Advance the MyGenera™ platform and broaden its therapeutic pipeline

 

“Sono entusiasta di entrare in un’azienda che rappresenta un’eccellenza italiana nella ricerca biotecnologica. Credo fortemente nel potenziale scientifico di Biogenera e nella sua capacità di portare soluzioni concrete dove oggi la medicina ha ancora bisogno di fare passi avanti.”
Massimiliano Cesarini, CEO di Biogenera

 

Leading the Future of Precision Therapies

Cesarini’s appointment reinforces Biogenera’s commitment to becoming a leading force in DNA-targeted precision medicine, with a focus on developing anti-gene oligonucleotide therapies that can change the treatment landscape for high-need patient populations.

en_USEnglish